Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sarah F Adams
NRG Oncology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- Hartford Hospital
Hartford, Connecticut, United States
- Augusta University Medical Center
Augusta, Georgia, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Uhhs-Chagrin Highlands Medical Center
Beachwood, Ohio, United States
- Case Western Reserve University
Cleveland, Ohio, United States
- Cleveland Clinic Foundation
Cleveland, Ohio, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- Women and Infants Hospital
Providence, Rhode Island, United States
- Ut Md Anderson Cancer Center
Houston, Texas, United States
- University of Virginia Cancer Center
Charlottesville, Virginia, United States
- Vcu Massey Comprehensive Cancer Center
Richmond, Virginia, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Dec 2019
- Primary completion
- 31 Jul 2021
- Completion
- 21 Feb 2027
- Last update posted
- 17 Jun 2026
- Registered enrollment
- 61
- Registry id
- NCT04034927
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.